Biochim Biophys Acta 691: 345352
Animal study The C57BL/6 mice (male, 56 weeks old) were purchased from SPF (Beijing) Biotechnology Co., Ltd
The regulatory framework for workplace testing, established by SAMHSA guidelines, does not include peptides and shows no movement toward including them
For those incorporating it into a weight loss program, injections are typically scheduled once per week to maintain energy and support metabolic function
Expert administration
CagriSema is a fixed-dose combination therapy comprising two molecules administered together in a single once-weekly subcutaneous injection: semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist already approved for weight management as Wegovy, and cagrilintide 2.4 mg, a long-acting analogue of amylin, a hormone involved in appetite regulation and satiety signalling